Monday, 31 August 2026European Markets

GYLDENDAL Stock Went Up By Over 9% So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of GYLDENDAL (Oslo Børs Benchmark Index_GI: GYL.OL) jumped 9.38% to kr525.00 at 11:37 EST on Tuesday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is dropping 0.49% to kr1,213.86, following the last session's upward trend. This seems, up to now, a somewhat bearish trend trading session today.

About GYLDENDAL

Gyldendal ASA, through its subsidiaries publishes and sells books in Norway. It also operates 143 bookstores and an online bookstore. In addition, it publishes dictionaries and encyclopedias; and provides logistics and reporting services to the book industry. The company was founded in 1925 and is based in Oslo, Norway. Gyldendal ASA is a subsidiary of Erik Must AS.

Earnings Per Share

As for profitability, GYLDENDAL has a trailing twelve months EPS of kr9.57.

PE Ratio

GYLDENDAL has a trailing twelve months price to earnings ratio of 54.86. Meaning, the purchaser of the share is investing kr54.86 for every norwegian krone of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GYLDENDAL's stock is considered to be overbought (>=80).

More news about GYLDENDAL (GYL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com